STEM vs. ULBI, GWH, CBAT, NVX, ELVA, DFLI, FLUX, SES, ITI, and NOTE
Should you be buying Stem stock or one of its competitors? The main competitors of Stem include Ultralife (ULBI), ESS Tech (GWH), CBAK Energy Technology (CBAT), NOVONIX (NVX), Electrovaya (ELVA), Dragonfly Energy (DFLI), Flux Power (FLUX), SES AI (SES), Iteris (ITI), and FiscalNote (NOTE). These companies are all part of the "computer and technology" sector.
Stem (NYSE:STEM) and Ultralife (NASDAQ:ULBI) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
61.6% of Stem shares are owned by institutional investors. Comparatively, 30.7% of Ultralife shares are owned by institutional investors. 10.2% of Stem shares are owned by insiders. Comparatively, 42.7% of Ultralife shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Stem currently has a consensus target price of $4.77, indicating a potential upside of 249.68%. Ultralife has a consensus target price of $13.00, indicating a potential upside of 12.95%. Given Stem's higher possible upside, analysts plainly believe Stem is more favorable than Ultralife.
Ultralife has lower revenue, but higher earnings than Stem. Stem is trading at a lower price-to-earnings ratio than Ultralife, indicating that it is currently the more affordable of the two stocks.
In the previous week, Ultralife had 2 more articles in the media than Stem. MarketBeat recorded 2 mentions for Ultralife and 0 mentions for Stem. Ultralife's average media sentiment score of 1.89 beat Stem's score of 0.00 indicating that Ultralife is being referred to more favorably in the news media.
Ultralife received 233 more outperform votes than Stem when rated by MarketBeat users. Likewise, 71.51% of users gave Ultralife an outperform vote while only 41.18% of users gave Stem an outperform vote.
Ultralife has a net margin of 6.19% compared to Stem's net margin of -40.03%. Ultralife's return on equity of 10.31% beat Stem's return on equity.
Stem has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Ultralife has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Summary
Ultralife beats Stem on 13 of the 18 factors compared between the two stocks.
Get Stem News Delivered to You Automatically
Sign up to receive the latest news and ratings for STEM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding STEM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
